Stem definition | Drug id | CAS RN |
---|---|---|
serotonin and/or norepinephrine reuptake inhibitors, fluoxetine derivatives | 4806 | 508233-74-7 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 35.30 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 72 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 30, 2013 | FDA | TAKEDA PHARMS USA | |
Sept. 20, 2019 | PMDA | Takeda Pharmaceutical Company Limited |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nausea | 929.88 | 39.67 | 397 | 2017 | 111792 | 2243879 |
Pruritus | 562.09 | 39.67 | 214 | 2200 | 43126 | 2312545 |
Suicidal ideation | 536.02 | 39.67 | 149 | 2265 | 10938 | 2344733 |
Vomiting | 277.18 | 39.67 | 153 | 2261 | 71449 | 2284222 |
Anxiety | 180.36 | 39.67 | 86 | 2328 | 29273 | 2326398 |
Depression | 150.42 | 39.67 | 75 | 2339 | 28057 | 2327614 |
Rash | 147.81 | 39.67 | 96 | 2318 | 59462 | 2296209 |
Feeling abnormal | 138.32 | 39.67 | 67 | 2347 | 23514 | 2332157 |
Headache | 137.55 | 39.67 | 103 | 2311 | 80076 | 2275595 |
Mania | 136.67 | 39.67 | 37 | 2377 | 2403 | 2353268 |
Anger | 131.02 | 39.67 | 36 | 2378 | 2471 | 2353200 |
Suicide attempt | 124.42 | 39.67 | 50 | 2364 | 11232 | 2344439 |
Insomnia | 115.28 | 39.67 | 61 | 2353 | 25726 | 2329945 |
Agitation | 111.64 | 39.67 | 46 | 2368 | 11005 | 2344666 |
Dizziness | 106.24 | 39.67 | 78 | 2336 | 58587 | 2297084 |
Serotonin syndrome | 106.00 | 39.67 | 33 | 2381 | 3507 | 2352164 |
Irritability | 105.12 | 39.67 | 38 | 2376 | 6389 | 2349282 |
Tremor | 101.23 | 39.67 | 52 | 2362 | 20609 | 2335062 |
Constipation | 96.13 | 39.67 | 51 | 2363 | 21578 | 2334093 |
No adverse event | 93.96 | 39.67 | 39 | 2375 | 9489 | 2346182 |
Weight increased | 91.80 | 39.67 | 50 | 2364 | 22287 | 2333384 |
Completed suicide | 91.79 | 39.67 | 49 | 2365 | 20985 | 2334686 |
Abnormal dreams | 82.41 | 39.67 | 25 | 2389 | 2433 | 2353238 |
Crying | 79.44 | 39.67 | 28 | 2386 | 4368 | 2351303 |
Intentional overdose | 77.98 | 39.67 | 36 | 2378 | 11285 | 2344386 |
Somnolence | 76.05 | 39.67 | 45 | 2369 | 23440 | 2332231 |
Hyponatraemia | 75.37 | 39.67 | 37 | 2377 | 13288 | 2342383 |
Nightmare | 72.38 | 39.67 | 25 | 2389 | 3672 | 2351999 |
Wrong technique in product usage process | 64.32 | 39.67 | 38 | 2376 | 19710 | 2335961 |
Diarrhoea | 63.58 | 39.67 | 68 | 2346 | 83496 | 2272175 |
Vision blurred | 60.64 | 39.67 | 33 | 2381 | 14635 | 2341036 |
Contusion | 59.08 | 39.67 | 31 | 2383 | 12779 | 2342892 |
Drug ineffective | 52.77 | 39.67 | 68 | 2346 | 101556 | 2254115 |
Urticaria | 52.34 | 39.67 | 36 | 2378 | 24225 | 2331446 |
Energy increased | 50.50 | 39.67 | 12 | 2402 | 457 | 2355214 |
Sexual dysfunction | 49.11 | 39.67 | 11 | 2403 | 321 | 2355350 |
Off label use | 47.47 | 39.67 | 55 | 2359 | 73543 | 2282128 |
Palpitations | 46.68 | 39.67 | 29 | 2385 | 16427 | 2339244 |
Fatigue | 45.90 | 39.67 | 58 | 2356 | 84815 | 2270856 |
Blood pressure increased | 45.84 | 39.67 | 29 | 2385 | 16957 | 2338714 |
Hyperhidrosis | 45.84 | 39.67 | 28 | 2386 | 15394 | 2340277 |
Product use in unapproved indication | 45.72 | 39.67 | 25 | 2389 | 11175 | 2344496 |
Electrocardiogram QT prolonged | 45.04 | 39.67 | 22 | 2392 | 7792 | 2347879 |
Vertigo | 44.07 | 39.67 | 23 | 2391 | 9361 | 2346310 |
Drug abuse | 44.05 | 39.67 | 25 | 2389 | 12001 | 2343670 |
Antipsychotic drug level above therapeutic | 43.53 | 39.67 | 9 | 2405 | 178 | 2355493 |
Aggression | 41.82 | 39.67 | 18 | 2396 | 4768 | 2350903 |
Overdose | 41.64 | 39.67 | 29 | 2385 | 19878 | 2335793 |
Sopor | 41.52 | 39.67 | 17 | 2397 | 3978 | 2351693 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Suicidal ideation | 296.33 | 39.21 | 83 | 1013 | 8435 | 1737250 |
Completed suicide | 267.09 | 39.21 | 89 | 1007 | 16223 | 1729462 |
Nausea | 195.08 | 39.21 | 98 | 998 | 51098 | 1694587 |
Anxiety | 159.02 | 39.21 | 60 | 1036 | 15467 | 1730218 |
Sexual dysfunction | 101.96 | 39.21 | 26 | 1070 | 1797 | 1743888 |
Vomiting | 101.65 | 39.21 | 58 | 1038 | 38257 | 1707428 |
Feeling abnormal | 88.70 | 39.21 | 36 | 1060 | 11130 | 1734555 |
Suicide attempt | 73.31 | 39.21 | 28 | 1068 | 7353 | 1738332 |
Drug ineffective | 72.46 | 39.21 | 57 | 1039 | 63744 | 1681941 |
Agitation | 65.67 | 39.21 | 29 | 1067 | 10997 | 1734688 |
Mania | 61.17 | 39.21 | 18 | 1078 | 2115 | 1743570 |
Dizziness | 60.12 | 39.21 | 40 | 1056 | 34321 | 1711364 |
Headache | 57.69 | 39.21 | 39 | 1057 | 34337 | 1711348 |
Depression | 57.10 | 39.21 | 30 | 1066 | 16639 | 1729046 |
Intentional overdose | 51.58 | 39.21 | 22 | 1074 | 7648 | 1738037 |
Erectile dysfunction | 44.37 | 39.21 | 17 | 1079 | 4480 | 1741205 |
Serotonin syndrome | 44.31 | 39.21 | 15 | 1081 | 2773 | 1742912 |
Insomnia | 41.15 | 39.21 | 24 | 1072 | 16252 | 1729433 |
Weight increased | 40.43 | 39.21 | 21 | 1075 | 11336 | 1734349 |
Source | Code | Description |
---|---|---|
ATC | N06AX26 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants |
CHEBI has role | CHEBI:35469 | antidepressant |
CHEBI has role | CHEBI:35474 | anxiolytic drug |
CHEBI has role | CHEBI:35941 | serotonergic agonist |
CHEBI has role | CHEBI:48279 | serotonergic antagonist |
MeSH PA | D014151 | Anti-Anxiety Agents |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D058825 | Serotonin 5-HT1 Receptor Agonists |
MeSH PA | D058831 | Serotonin 5-HT3 Receptor Antagonists |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D012702 | Serotonin Antagonists |
MeSH PA | D017366 | Serotonin Receptor Agonists |
MeSH PA | D017367 | Serotonin Uptake Inhibitors |
MeSH PA | D014149 | Tranquilizing Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Major depressive disorder | indication | 370143000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.02 | Basic |
pKa2 | 1.85 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8476279 | Oct. 2, 2022 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 8476279 | Oct. 2, 2022 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8476279 | Oct. 2, 2022 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8476279 | Oct. 2, 2022 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 7144884 | June 17, 2026 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 7144884 | June 17, 2026 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 7144884 | June 17, 2026 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 7144884 | June 17, 2026 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8969355 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125908 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125909 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125910 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9227946 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9861630 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 8969355 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9125908 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9125909 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9125910 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9227946 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9861630 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8969355 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125908 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125909 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125910 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9227946 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9861630 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 8969355 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125908 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125909 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9125910 | June 15, 2027 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9227946 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9861630 | June 15, 2027 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9278096 | March 21, 2032 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | 9278096 | March 21, 2032 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9278096 | March 21, 2032 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | 9278096 | March 21, 2032 | USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | May 2, 2021 | ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | May 2, 2021 | ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | May 2, 2021 | ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | May 2, 2021 | ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER |
EQ 10MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Oct. 19, 2021 | UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS |
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | DISCN | TABLET | ORAL | Oct. 19, 2021 | UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS |
EQ 20MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Oct. 19, 2021 | UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS |
EQ 5MG BASE | TRINTELLIX | TAKEDA PHARMS USA | N204447 | Sept. 30, 2013 | RX | TABLET | ORAL | Oct. 19, 2021 | UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 7.82 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Ki | 8.80 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 7.72 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 1D | GPCR | ANTAGONIST | Ki | 7.27 | DRUG LABEL | DRUG LABEL | |||
5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 7.48 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 3A | Ion channel | ANTAGONIST | Ki | 8.43 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
Histamine H2 receptor | GPCR | Ki | 6.74 | CHEMBL | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.74 | CHEMBL | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.74 | CHEMBL | |||||
Histamine H1 receptor | GPCR | Ki | 6.74 | CHEMBL | |||||
5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.66 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.48 | CHEMBL | |||||
Beta-2 adrenergic receptor | GPCR | Ki | 6.25 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Ki | 7.34 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | IC50 | 8.28 | CHEMBL | |||||
5-hydroxytryptamine receptor 1D | GPCR | ANTAGONIST | IC50 | 5.40 | IUPHAR | ||||
5-hydroxytryptamine receptor 7 | GPCR | Ki | 6.70 | SCIENTIFIC LITERATURE | |||||
Sodium-dependent dopamine transporter | Transporter | IC50 | 6.05 | CHEMBL | |||||
5-hydroxytryptamine receptor 3A | Ion channel | Ki | 6.64 | CHEMBL |
ID | Source |
---|---|
D000078784 | MESH_DESCRIPTOR_UI |
D10184 | KEGG_DRUG |
C3667599 | UMLSCUI |
3O2K1S3WQV | UNII |
9279 | INN_ID |
768282000 | SNOMEDCT_US |
015226 | NDDF |
d08125 | MMSL |
1455099 | RXNORM |
4032784 | VANDF |
708717008 | SNOMEDCT_US |
9966051 | PUBCHEM_CID |
CHEBI:76016 | CHEBI |
960203-27-4 | SECONDARY_CAS_RN |
DB09068 | DRUGBANK_ID |
CHEMBL2104993 | ChEMBL_ID |
CHEMBL2107387 | ChEMBL_ID |
7351 | IUPHAR_LIGAND_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0256 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 21 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0257 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 21 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-720 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 21 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-730 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 21 sections |
Trintellix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64764-750 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 21 sections |